Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2199)	6/2/2010 1:06:56 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AMGN is also reversing its trend from yesterday.<g> The stock was up 9.04% and is still up 8.53% with volume now > 2.18x its ADV The stock opened with a good UG bigcharts.marketwatch.com The FDA approved AMGN's Prolia for osteoporosis drug, seven weeks ahead of schedule.<g> Prolia is expected to capture large portions of the osteoporosis drug markets, with annual sales of up to $1B as treatment for osteoporosis in post-menopausal woman and bone loss in men with prostatic Ca. AMGN has reported netter revenues in the last 2Qs and earnings were also 20% better in the 1stQ. ($1.30 vs. $1.08) The EE for 2010 & 2011 are around $5.10 & $5.50 vs. $4.91 in 2009 The stock is trying today to get off from its near term DT, coming from its April H at $61.26 bigcharts.marketwatch.com The ACTAY is $68.36 However, AMGN has a good amount of resistance from the $60 to the $65 level. bigcharts.marketwatch.com Bernard